Endomedix was founded in 2005 with a focus of developing hydrogel technology within the medical device market. The company was initially capitalized with over $1 million in private and government funding has eight patents filed. In 2006, the company signed its first licensing agreement with Fortune 500 Company. The entire market for biomaterials in medical device is well over $4 Billion annually.

Core Technology:

      • An Environmentally Responsive, Biodegradable Hydrogel
      • Made from Natural Materials, not Derived from Blood Products
      • Hydrogel Versatility to Span Many Markets Including General Surgery, Neurosurgery, Orthopedic Surgery, Vascular Surgery, and Cosmetics
      • Excellent for Drug Delivery (Cancer, Stroke, Pain)
      • Strong Hemostat
      • Naturally Antibacterial
      • Promotes Wound Healing and Superior to Current Standard